| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 85 | 2024 | 509 | 9.500 |
Why?
|
| Pancreatectomy | 30 | 2022 | 56 | 4.460 |
Why?
|
| Pancreaticoduodenectomy | 26 | 2019 | 42 | 4.340 |
Why?
|
| Adenocarcinoma | 34 | 2024 | 287 | 3.910 |
Why?
|
| Laparoscopy | 13 | 2019 | 143 | 3.760 |
Why?
|
| Neuroendocrine Tumors | 14 | 2021 | 29 | 3.620 |
Why?
|
| Carcinoma, Pancreatic Ductal | 21 | 2024 | 129 | 2.540 |
Why?
|
| Aged | 78 | 2024 | 5223 | 1.530 |
Why?
|
| Middle Aged | 75 | 2024 | 6907 | 1.370 |
Why?
|
| Humans | 130 | 2024 | 27143 | 1.310 |
Why?
|
| Male | 90 | 2024 | 13017 | 1.300 |
Why?
|
| Female | 96 | 2024 | 14634 | 1.230 |
Why?
|
| Adenocarcinoma, Mucinous | 6 | 2016 | 10 | 1.230 |
Why?
|
| Retrospective Studies | 46 | 2021 | 2465 | 1.180 |
Why?
|
| Pancreatic Cyst | 7 | 2019 | 8 | 1.130 |
Why?
|
| Prognosis | 34 | 2023 | 762 | 1.120 |
Why?
|
| Liver Neoplasms | 12 | 2016 | 164 | 1.030 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2013 | 467 | 1.020 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2016 | 4 | 0.990 |
Why?
|
| Aged, 80 and over | 38 | 2024 | 1939 | 0.910 |
Why?
|
| Treatment Outcome | 28 | 2019 | 2286 | 0.820 |
Why?
|
| Carcinoma, Neuroendocrine | 6 | 2012 | 14 | 0.820 |
Why?
|
| Neoplasm Staging | 18 | 2022 | 463 | 0.810 |
Why?
|
| Adult | 47 | 2020 | 7498 | 0.800 |
Why?
|
| Ampulla of Vater | 3 | 2017 | 6 | 0.750 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 30 | 0.700 |
Why?
|
| Hepatectomy | 11 | 2016 | 26 | 0.690 |
Why?
|
| Cancer Vaccines | 7 | 2020 | 32 | 0.670 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2017 | 5 | 0.660 |
Why?
|
| Genomics | 1 | 2020 | 116 | 0.660 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 989 | 0.650 |
Why?
|
| Adenoma | 3 | 2017 | 59 | 0.640 |
Why?
|
| Receptors, Cell Surface | 2 | 2017 | 109 | 0.630 |
Why?
|
| Choledochal Cyst | 2 | 2009 | 5 | 0.620 |
Why?
|
| Nomograms | 2 | 2015 | 9 | 0.580 |
Why?
|
| Thrombelastography | 1 | 2018 | 46 | 0.580 |
Why?
|
| Suture Techniques | 2 | 2014 | 28 | 0.560 |
Why?
|
| Patient Care Planning | 2 | 2016 | 24 | 0.550 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 2 | 0.540 |
Why?
|
| Length of Stay | 7 | 2019 | 218 | 0.540 |
Why?
|
| Digestive System Neoplasms | 1 | 2016 | 5 | 0.530 |
Why?
|
| Neoplasms | 7 | 2023 | 767 | 0.520 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2016 | 2 | 0.520 |
Why?
|
| Spleen | 1 | 2016 | 109 | 0.520 |
Why?
|
| Patient Care Team | 1 | 2016 | 62 | 0.520 |
Why?
|
| Pancreas | 4 | 2019 | 58 | 0.500 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 657 | 0.500 |
Why?
|
| Survival Rate | 20 | 2020 | 412 | 0.500 |
Why?
|
| Cell Adhesion Molecules | 1 | 2016 | 64 | 0.500 |
Why?
|
| Learning Curve | 1 | 2015 | 13 | 0.490 |
Why?
|
| Colorectal Neoplasms | 5 | 2017 | 133 | 0.490 |
Why?
|
| Pancreaticojejunostomy | 1 | 2014 | 1 | 0.480 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 34 | 0.480 |
Why?
|
| Sutures | 1 | 2014 | 15 | 0.480 |
Why?
|
| Robotics | 1 | 2015 | 42 | 0.480 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 62 | 0.470 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 280 | 0.450 |
Why?
|
| Pancreatic Diseases | 4 | 2020 | 13 | 0.450 |
Why?
|
| Deoxycytidine | 4 | 2024 | 63 | 0.450 |
Why?
|
| Postoperative Complications | 10 | 2019 | 606 | 0.430 |
Why?
|
| Survival Analysis | 10 | 2017 | 279 | 0.420 |
Why?
|
| Predictive Value of Tests | 9 | 2018 | 472 | 0.400 |
Why?
|
| Lymphatic Metastasis | 9 | 2018 | 119 | 0.400 |
Why?
|
| Immunotherapy | 7 | 2021 | 137 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 375 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 69 | 0.400 |
Why?
|
| Endosonography | 4 | 2016 | 36 | 0.400 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2012 | 5 | 0.400 |
Why?
|
| Somatostatin | 1 | 2012 | 25 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2014 | 312 | 0.380 |
Why?
|
| Drainage | 3 | 2019 | 42 | 0.370 |
Why?
|
| Bronchogenic Cyst | 1 | 2010 | 1 | 0.350 |
Why?
|
| Lymph Node Excision | 2 | 2010 | 96 | 0.350 |
Why?
|
| Nephrectomy | 1 | 2010 | 47 | 0.340 |
Why?
|
| Anemia | 1 | 2010 | 41 | 0.340 |
Why?
|
| Cholecystectomy | 2 | 2010 | 15 | 0.340 |
Why?
|
| Stomach Neoplasms | 1 | 2009 | 19 | 0.330 |
Why?
|
| Gastrectomy | 1 | 2009 | 19 | 0.330 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2010 | 77 | 0.330 |
Why?
|
| Radiography | 3 | 2016 | 201 | 0.330 |
Why?
|
| Cell Line, Tumor | 10 | 2023 | 1269 | 0.330 |
Why?
|
| Kidney Neoplasms | 1 | 2010 | 100 | 0.320 |
Why?
|
| Robotic Surgical Procedures | 2 | 2019 | 43 | 0.320 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2024 | 46 | 0.310 |
Why?
|
| Cation Transport Proteins | 2 | 2019 | 60 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2016 | 130 | 0.290 |
Why?
|
| Mice | 13 | 2024 | 4467 | 0.290 |
Why?
|
| Thoracic Injuries | 1 | 2007 | 4 | 0.290 |
Why?
|
| Pleura | 1 | 2007 | 4 | 0.290 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2007 | 10 | 0.290 |
Why?
|
| Foreign Bodies | 1 | 2007 | 16 | 0.280 |
Why?
|
| Combined Modality Therapy | 10 | 2023 | 292 | 0.280 |
Why?
|
| Wounds, Penetrating | 1 | 2007 | 23 | 0.280 |
Why?
|
| Risk Assessment | 8 | 2016 | 594 | 0.280 |
Why?
|
| DNA Helicases | 3 | 2012 | 51 | 0.270 |
Why?
|
| Mutation | 6 | 2015 | 821 | 0.270 |
Why?
|
| B7-H1 Antigen | 2 | 2018 | 35 | 0.270 |
Why?
|
| Young Adult | 10 | 2017 | 2629 | 0.260 |
Why?
|
| Operative Time | 2 | 2017 | 40 | 0.260 |
Why?
|
| Fluorouracil | 7 | 2019 | 53 | 0.260 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2012 | 161 | 0.260 |
Why?
|
| Animals | 16 | 2024 | 10069 | 0.250 |
Why?
|
| Respiratory Insufficiency | 1 | 2005 | 13 | 0.250 |
Why?
|
| Traumatology | 1 | 2005 | 19 | 0.250 |
Why?
|
| Peritoneal Neoplasms | 2 | 2017 | 76 | 0.240 |
Why?
|
| Nuclear Proteins | 3 | 2012 | 245 | 0.240 |
Why?
|
| Resuscitation | 1 | 2005 | 59 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 234 | 0.240 |
Why?
|
| Biomarkers, Tumor | 4 | 2015 | 377 | 0.230 |
Why?
|
| Algorithms | 2 | 2019 | 422 | 0.230 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 37 | 0.230 |
Why?
|
| Theranostic Nanomedicine | 1 | 2024 | 22 | 0.230 |
Why?
|
| Pediatrics | 1 | 2005 | 87 | 0.230 |
Why?
|
| Emergency Service, Hospital | 1 | 2005 | 119 | 0.220 |
Why?
|
| Cystadenoma, Mucinous | 2 | 2015 | 2 | 0.220 |
Why?
|
| Cell Proliferation | 4 | 2019 | 774 | 0.220 |
Why?
|
| Preoperative Care | 4 | 2018 | 76 | 0.210 |
Why?
|
| Ki-67 Antigen | 2 | 2013 | 23 | 0.210 |
Why?
|
| Adolescent | 8 | 2017 | 2991 | 0.210 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 2 | 2016 | 19 | 0.210 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 188 | 0.210 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 168 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 9 | 2013 | 180 | 0.210 |
Why?
|
| Risk Factors | 12 | 2019 | 2036 | 0.210 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2018 | 189 | 0.200 |
Why?
|
| Carcinoma | 3 | 2011 | 72 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2012 | 139 | 0.200 |
Why?
|
| Carcinoma, Papillary | 3 | 2012 | 18 | 0.200 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2020 | 70 | 0.200 |
Why?
|
| Esophageal Neoplasms | 2 | 2017 | 31 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2021 | 10 | 0.190 |
Why?
|
| Pancreatic Fistula | 2 | 2019 | 14 | 0.190 |
Why?
|
| Cystadenoma, Serous | 2 | 2011 | 3 | 0.190 |
Why?
|
| Telomere | 2 | 2012 | 32 | 0.190 |
Why?
|
| Neuroendocrine Cells | 1 | 2021 | 1 | 0.190 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 2021 | 2 | 0.190 |
Why?
|
| United States | 10 | 2021 | 2062 | 0.190 |
Why?
|
| Listeria monocytogenes | 2 | 2012 | 58 | 0.190 |
Why?
|
| Decision Making | 2 | 2014 | 170 | 0.190 |
Why?
|
| Carcinoma in Situ | 2 | 2012 | 44 | 0.190 |
Why?
|
| Sarcopenia | 2 | 2012 | 42 | 0.190 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 117 | 0.180 |
Why?
|
| Exosomes | 1 | 2023 | 86 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 44 | 0.180 |
Why?
|
| Palliative Care | 2 | 2012 | 79 | 0.180 |
Why?
|
| Hypertension | 1 | 2003 | 305 | 0.180 |
Why?
|
| Tattooing | 2 | 2010 | 6 | 0.180 |
Why?
|
| Reproducibility of Results | 5 | 2014 | 751 | 0.180 |
Why?
|
| Nanoparticles | 1 | 2024 | 276 | 0.170 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 3 | 2016 | 14 | 0.170 |
Why?
|
| Lymphocytes | 1 | 2020 | 83 | 0.170 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2018 | 35 | 0.170 |
Why?
|
| Liver | 3 | 2012 | 424 | 0.170 |
Why?
|
| Diabetic Angiopathies | 1 | 2020 | 48 | 0.170 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2012 | 160 | 0.170 |
Why?
|
| Gene Expression Regulation | 1 | 2003 | 627 | 0.170 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 157 | 0.170 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 61 | 0.170 |
Why?
|
| Proportional Hazards Models | 7 | 2016 | 217 | 0.170 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.170 |
Why?
|
| Integrin alpha3 | 1 | 2019 | 18 | 0.170 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 298 | 0.170 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 1 | 2019 | 26 | 0.170 |
Why?
|
| Societies, Medical | 1 | 2020 | 89 | 0.160 |
Why?
|
| Lymph Nodes | 4 | 2012 | 97 | 0.160 |
Why?
|
| Cohort Studies | 8 | 2016 | 865 | 0.160 |
Why?
|
| Elective Surgical Procedures | 1 | 2019 | 70 | 0.160 |
Why?
|
| Thalidomide | 1 | 2018 | 10 | 0.160 |
Why?
|
| Neutrophils | 2 | 2017 | 179 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 141 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2018 | 20 | 0.150 |
Why?
|
| Esophagectomy | 2 | 2017 | 8 | 0.150 |
Why?
|
| SEER Program | 4 | 2011 | 46 | 0.150 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2018 | 33 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 150 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2018 | 48 | 0.150 |
Why?
|
| Extracellular Vesicles | 1 | 2018 | 35 | 0.150 |
Why?
|
| Appendiceal Neoplasms | 1 | 2017 | 5 | 0.150 |
Why?
|
| Prospective Studies | 7 | 2019 | 1223 | 0.150 |
Why?
|
| Cachexia | 1 | 2018 | 51 | 0.150 |
Why?
|
| Signal Transduction | 4 | 2019 | 1374 | 0.150 |
Why?
|
| Coronary Artery Disease | 1 | 2020 | 216 | 0.150 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2017 | 31 | 0.140 |
Why?
|
| Diagnostic Imaging | 2 | 2022 | 64 | 0.140 |
Why?
|
| Quality of Life | 2 | 2019 | 464 | 0.140 |
Why?
|
| Hyperthermia, Induced | 1 | 2017 | 30 | 0.140 |
Why?
|
| Trastuzumab | 1 | 2017 | 12 | 0.140 |
Why?
|
| Immunohistochemistry | 6 | 2015 | 455 | 0.140 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2015 | 37 | 0.140 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2017 | 3 | 0.140 |
Why?
|
| Pylorus | 1 | 2017 | 4 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 61 | 0.140 |
Why?
|
| Neuromuscular Agents | 1 | 2017 | 5 | 0.140 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 8 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 104 | 0.140 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 7 | 0.140 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2017 | 9 | 0.140 |
Why?
|
| Receptors, Immunologic | 1 | 2017 | 64 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2017 | 78 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2013 | 12 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 38 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2018 | 82 | 0.140 |
Why?
|
| Smad4 Protein | 2 | 2013 | 5 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 323 | 0.140 |
Why?
|
| Quinazolines | 2 | 2013 | 31 | 0.140 |
Why?
|
| Incidental Findings | 1 | 2016 | 14 | 0.130 |
Why?
|
| Tumor Burden | 2 | 2014 | 108 | 0.130 |
Why?
|
| Endoscopy, Digestive System | 1 | 2016 | 19 | 0.130 |
Why?
|
| Molecular Sequence Data | 2 | 2016 | 1037 | 0.130 |
Why?
|
| Nectins | 1 | 2016 | 2 | 0.130 |
Why?
|
| Receptors, Virus | 1 | 2016 | 6 | 0.130 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 6 | 0.130 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2016 | 19 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 14 | 0.130 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2016 | 30 | 0.130 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2016 | 130 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 75 | 0.130 |
Why?
|
| Medical Oncology | 1 | 2016 | 86 | 0.130 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2015 | 2 | 0.130 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2015 | 3 | 0.130 |
Why?
|
| Patient Selection | 2 | 2013 | 143 | 0.120 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 2 | 2012 | 3 | 0.120 |
Why?
|
| Ligands | 1 | 2016 | 168 | 0.120 |
Why?
|
| Survivors | 1 | 2015 | 36 | 0.120 |
Why?
|
| HEK293 Cells | 1 | 2016 | 176 | 0.120 |
Why?
|
| Anastomosis, Surgical | 1 | 2015 | 37 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2016 | 94 | 0.120 |
Why?
|
| ras Proteins | 2 | 2012 | 43 | 0.120 |
Why?
|
| Vitamin B Complex | 1 | 2014 | 4 | 0.120 |
Why?
|
| Leucovorin | 1 | 2014 | 16 | 0.120 |
Why?
|
| Duodenal Neoplasms | 2 | 2011 | 6 | 0.120 |
Why?
|
| Immunoglobulins | 1 | 2014 | 33 | 0.120 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 204 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2016 | 229 | 0.120 |
Why?
|
| Perioperative Period | 2 | 2011 | 7 | 0.120 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2014 | 27 | 0.120 |
Why?
|
| Mesothelioma, Cystic | 1 | 2014 | 1 | 0.120 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2014 | 9 | 0.120 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 50 | 0.120 |
Why?
|
| Fertility Preservation | 1 | 2014 | 8 | 0.120 |
Why?
|
| Models, Molecular | 1 | 2016 | 445 | 0.110 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 16 | 0.110 |
Why?
|
| Dendritic Cells | 1 | 2016 | 143 | 0.110 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 675 | 0.110 |
Why?
|
| Analysis of Variance | 5 | 2013 | 388 | 0.110 |
Why?
|
| Equipment Design | 1 | 2014 | 211 | 0.110 |
Why?
|
| Mitotic Index | 1 | 2013 | 3 | 0.110 |
Why?
|
| Catheter Ablation | 3 | 2011 | 220 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2011 | 52 | 0.110 |
Why?
|
| Diagnosis, Differential | 5 | 2015 | 368 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 49 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2013 | 19 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2013 | 58 | 0.110 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 509 | 0.110 |
Why?
|
| Phylogeny | 1 | 2016 | 463 | 0.110 |
Why?
|
| Neoplasm Metastasis | 4 | 2019 | 151 | 0.110 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 86 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2011 | 110 | 0.110 |
Why?
|
| Phenotype | 4 | 2020 | 666 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 33 | 0.100 |
Why?
|
| Psoas Muscles | 1 | 2012 | 2 | 0.100 |
Why?
|
| Hospital Mortality | 4 | 2016 | 148 | 0.100 |
Why?
|
| Biological Therapy | 1 | 2012 | 5 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2012 | 39 | 0.100 |
Why?
|
| Biliopancreatic Diversion | 1 | 2012 | 1 | 0.100 |
Why?
|
| Colectomy | 1 | 2012 | 4 | 0.100 |
Why?
|
| Loss of Heterozygosity | 1 | 2012 | 11 | 0.100 |
Why?
|
| Glycolipids | 1 | 2012 | 18 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2012 | 5 | 0.100 |
Why?
|
| Vascular Neoplasms | 1 | 2012 | 3 | 0.100 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 6 | 0.100 |
Why?
|
| Somatostatinoma | 1 | 2012 | 1 | 0.100 |
Why?
|
| Insulinoma | 1 | 2012 | 2 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2020 | 17 | 0.100 |
Why?
|
| Vipoma | 1 | 2012 | 2 | 0.100 |
Why?
|
| Gastrinoma | 1 | 2012 | 3 | 0.100 |
Why?
|
| Pancreatic Ducts | 1 | 2012 | 10 | 0.100 |
Why?
|
| Serotonin | 1 | 2012 | 16 | 0.100 |
Why?
|
| Papilloma, Intraductal | 1 | 2011 | 1 | 0.100 |
Why?
|
| Antigens | 1 | 2012 | 66 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2012 | 14 | 0.100 |
Why?
|
| Exome | 1 | 2011 | 30 | 0.100 |
Why?
|
| Mitosis | 1 | 2012 | 109 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 447 | 0.100 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 128 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2011 | 2 | 0.100 |
Why?
|
| Hyalin | 1 | 2011 | 2 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2012 | 77 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2016 | 231 | 0.090 |
Why?
|
| Annexin A2 | 1 | 2011 | 3 | 0.090 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2011 | 12 | 0.090 |
Why?
|
| Castleman Disease | 1 | 2011 | 2 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2012 | 68 | 0.090 |
Why?
|
| Cell Differentiation | 1 | 2013 | 398 | 0.090 |
Why?
|
| Tyrosine | 1 | 2011 | 91 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 91 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2020 | 191 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2012 | 103 | 0.090 |
Why?
|
| Melanoma | 1 | 2012 | 140 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2011 | 122 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 2011 | 61 | 0.090 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2010 | 6 | 0.090 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2010 | 5 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 1 | 2010 | 14 | 0.090 |
Why?
|
| Hematoma | 1 | 2010 | 26 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2011 | 76 | 0.090 |
Why?
|
| Age Factors | 4 | 2016 | 721 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 445 | 0.090 |
Why?
|
| Child | 2 | 2008 | 2165 | 0.090 |
Why?
|
| Mesenteric Veins | 1 | 2010 | 3 | 0.090 |
Why?
|
| Portal Vein | 1 | 2010 | 8 | 0.090 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2009 | 12 | 0.080 |
Why?
|
| Cell Membrane | 1 | 2011 | 236 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2010 | 60 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2010 | 116 | 0.080 |
Why?
|
| Duodenostomy | 1 | 2009 | 1 | 0.080 |
Why?
|
| Logistic Models | 3 | 2016 | 398 | 0.080 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 5 | 0.080 |
Why?
|
| Jejunostomy | 1 | 2009 | 4 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2013 | 197 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 310 | 0.080 |
Why?
|
| Chyle | 1 | 2008 | 2 | 0.080 |
Why?
|
| Chylous Ascites | 1 | 2008 | 3 | 0.080 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 225 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2023 | 29 | 0.080 |
Why?
|
| Mice, Nude | 2 | 2019 | 312 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2020 | 706 | 0.070 |
Why?
|
| Time Factors | 4 | 2016 | 1572 | 0.070 |
Why?
|
| X-linked Nuclear Protein | 3 | 2012 | 4 | 0.070 |
Why?
|
| Co-Repressor Proteins | 3 | 2012 | 8 | 0.070 |
Why?
|
| Hemothorax | 1 | 2007 | 2 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 341 | 0.070 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 88 | 0.070 |
Why?
|
| Molecular Chaperones | 3 | 2012 | 48 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2022 | 1405 | 0.070 |
Why?
|
| Sex Factors | 3 | 2016 | 451 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2011 | 80 | 0.070 |
Why?
|
| Comorbidity | 3 | 2012 | 251 | 0.060 |
Why?
|
| Intubation, Intratracheal | 1 | 2005 | 26 | 0.060 |
Why?
|
| Barrett Esophagus | 1 | 2005 | 16 | 0.060 |
Why?
|
| Surgical Wound Infection | 2 | 2019 | 104 | 0.060 |
Why?
|
| Capecitabine | 2 | 2016 | 3 | 0.060 |
Why?
|
| Injury Severity Score | 1 | 2005 | 117 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2019 | 566 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 1494 | 0.060 |
Why?
|
| Esophagus | 1 | 2005 | 69 | 0.060 |
Why?
|
| Trauma Centers | 1 | 2005 | 115 | 0.060 |
Why?
|
| General Surgery | 1 | 2005 | 53 | 0.060 |
Why?
|
| Obesity | 1 | 2010 | 651 | 0.060 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2013 | 10 | 0.060 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 44 | 0.060 |
Why?
|
| Flow Cytometry | 2 | 2015 | 285 | 0.060 |
Why?
|
| Disease Progression | 2 | 2017 | 458 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2015 | 64 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 14 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2003 | 240 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2003 | 220 | 0.050 |
Why?
|
| Lysosomes | 1 | 2023 | 55 | 0.050 |
Why?
|
| Interleukin-8 | 1 | 2022 | 44 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2003 | 538 | 0.050 |
Why?
|
| Myeloid Cells | 1 | 2022 | 27 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2024 | 216 | 0.050 |
Why?
|
| Clone Cells | 2 | 2012 | 20 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2012 | 72 | 0.050 |
Why?
|
| Morbidity | 2 | 2012 | 58 | 0.050 |
Why?
|
| World Health Organization | 1 | 2021 | 10 | 0.050 |
Why?
|
| Jaundice | 2 | 2011 | 3 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 61 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 264 | 0.050 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2011 | 21 | 0.050 |
Why?
|
| Systems Biology | 1 | 2020 | 21 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2020 | 71 | 0.040 |
Why?
|
| Blood Proteins | 1 | 2020 | 64 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 144 | 0.040 |
Why?
|
| Rats | 1 | 2003 | 1544 | 0.040 |
Why?
|
| Abdominal Pain | 2 | 2011 | 34 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2012 | 365 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2020 | 68 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 32 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 54 | 0.040 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Splenectomy | 2 | 2010 | 43 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 113 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2019 | 53 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 93 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 131 | 0.040 |
Why?
|
| Reoperation | 2 | 2010 | 144 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 175 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2018 | 26 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 45 | 0.040 |
Why?
|
| Immunity | 1 | 2018 | 26 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2018 | 29 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2021 | 340 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 213 | 0.040 |
Why?
|
| Random Allocation | 1 | 2018 | 148 | 0.040 |
Why?
|
| Machine Learning | 1 | 2019 | 81 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 199 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2018 | 56 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2018 | 35 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 250 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 33 | 0.040 |
Why?
|
| Incidence | 2 | 2009 | 553 | 0.030 |
Why?
|
| Gastric Emptying | 1 | 2017 | 8 | 0.030 |
Why?
|
| Biomarkers | 1 | 2020 | 736 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 933 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 438 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2016 | 18 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 11 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 137 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 65 | 0.030 |
Why?
|
| Safety | 1 | 2014 | 31 | 0.030 |
Why?
|
| Oocytes | 1 | 2014 | 24 | 0.030 |
Why?
|
| Cryopreservation | 1 | 2014 | 12 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 26 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 254 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2014 | 20 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 622 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 44 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 23 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2013 | 7 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 2013 | 63 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2013 | 102 | 0.030 |
Why?
|
| Immunotherapy, Active | 1 | 2012 | 6 | 0.030 |
Why?
|
| Biopsy | 1 | 2013 | 201 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Radiotherapy, Conformal | 1 | 2012 | 15 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 195 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 143 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2012 | 8 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 665 | 0.020 |
Why?
|
| Maryland | 1 | 2011 | 7 | 0.020 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2011 | 11 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2012 | 48 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 21 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2011 | 21 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 27 | 0.020 |
Why?
|
| CTLA-4 Antigen | 1 | 2011 | 10 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2011 | 21 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 90 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 7 | 0.020 |
Why?
|
| Cyst Fluid | 1 | 2011 | 2 | 0.020 |
Why?
|
| Chromogranins | 1 | 2011 | 2 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 64 | 0.020 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2011 | 1 | 0.020 |
Why?
|
| Neprilysin | 1 | 2011 | 2 | 0.020 |
Why?
|
| Ablation Techniques | 1 | 2011 | 12 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 25 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 25 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2011 | 4 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 647 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2011 | 17 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 70 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2011 | 47 | 0.020 |
Why?
|
| Medicare | 1 | 2012 | 119 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 62 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 121 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 45 | 0.020 |
Why?
|
| Cholestasis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2011 | 103 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2011 | 14 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 24 | 0.020 |
Why?
|
| beta Catenin | 1 | 2011 | 62 | 0.020 |
Why?
|
| Abdominal Abscess | 1 | 2011 | 9 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 37 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 280 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 57 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 135 | 0.020 |
Why?
|
| Stents | 1 | 2011 | 116 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2011 | 106 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2011 | 135 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2011 | 49 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 2010 | 3 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2010 | 3 | 0.020 |
Why?
|
| Cholangiocarcinoma | 1 | 2010 | 5 | 0.020 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 3 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 573 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2011 | 110 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 2010 | 13 | 0.020 |
Why?
|
| Weight Loss | 1 | 2011 | 71 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 134 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2011 | 253 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 91 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 383 | 0.020 |
Why?
|
| DNA | 1 | 2011 | 365 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 506 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 353 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 318 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2010 | 229 | 0.020 |
Why?
|
| Overweight | 1 | 2010 | 108 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 206 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 66 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2010 | 387 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 482 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 353 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 447 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2005 | 15 | 0.020 |
Why?
|